东诚药业：氟思睿肽注射液上市申请获受理

Core Viewpoint - Dongcheng Pharmaceutical's subsidiary, Lanacheng, has received the acceptance notice from the National Medical Products Administration for the marketing authorization application of the investigational drug, Fluorine-18 PSMA injection, which is a targeted radiopharmaceutical for PET imaging in prostate cancer patients [1] Group 1: Product Information - Fluorine-18 PSMA injection is designed for positron emission tomography (PET) imaging of prostate-specific membrane antigen (PSMA) positive lesions in prostate cancer patients [1] - There are currently no similar products available in the domestic market, while similar products are already available internationally [1] Group 2: Market Comparison - Lantheus Holdings' product, 18F-PSMA diagnostic agent PYLARIFY, reported sales revenue of $1.1 billion in its 2024 annual report [1]